< PreviousOUTSOURCING 30 Pharma Business International www.pbiforum.net house teams to regain time to focus on value-added tasks, while also removing the need for hiring of new staff – which is difficult in today’s economic climate and with a noted shortage of skilled recruitment targets. There are a number of core reasons why mid to large sized pharmaceutical companies choose to outsource. One of the main focuses is to reduce complexity of tasks and strain on in-house teams saving on necessary training and recruitment of new staff members. The recruitment market is not what it could be and it feels as if every industry is facing the same problem. Still, shortages in students studying STEM subjects have taken its toll on the industry, making recruitment of skilled staff (and retaining them in the face of constant headhunting) difficult. Outsourcing allows a company to step away from recruitment and use the staff of another company, and in the same vein of thought use their technology and infrastructure as well – saving on costs associated with investing in said technology. Additionally, the ever-changing regulations and requirements of the industry may add an extra burden to in- house teams to have to come to grasp with, but which outsourcing partners might already have experience dealing with. The correct outsourcing partner is obviously one with topical experience in the field or medicines a company works in, and good scouting and research of outsourcing partners is required to make sure they fit a business’s needs. Whether a company is looking to outsource responsibility to take advantage of a company’s resources or to free up their own staff to take on tasks more suited to adding value and earning profit is immaterial, however, as what is important is knowing how to manage outsourcing in an efficient and effective manner, as a piecemeal approach to outsourcing is likely to cause more problems than it solves. It’s important to select a partner that will take responsibility for any process or portfolios they are entrusted with, and preferably one with proven experience. This is obvious given that a new drug or portfolio is a company’s most important asset, and intellectual property is a tricky business at any stage – an outsourcing partner must therefore be prepared to take on responsibility as if it were their own. Pharma Business International 31 www.pbiforum.net The important thing to remember is that even though duties are outsourced, they are still working for you and in your interests, which means KPIs and other targets do still hold. Accurate monitoring and analysis of how an outsourcing partner is performing should be performed at regular intervals. A good partner will provide that information when asked, and sometimes even when not. Outsourcing is both an opportunity and a risk, but it is one that is becoming more common across the pharma industry as employment opportunities outstrip employees. This challenge is unlikely to end any time soon, so it is best companies adapt sooner than later. © stock.adobe.com/Chopard Photography © stock.adobe.com/GorodenkoffGene Therapy Process Development Summit 13 - 14 December Philadelphia, USA The first Gene Therapy Process Development Summit is your only specific gene therapy event with optimizing process development with the transgene at the forefront of mind. Join your biopharma colleagues from the likes of Ultragenyx, Janssen, REGENXBIO and more, for two days of cutting-edge talks on cell-line development, scale-up, transfection, purification, analytics, and regulation. This must-attend meeting is your chance to share ideas, successes, and challenges, and capitalize on the latest advances in process development to bring safe and effective drugs to patients faster. Pre-Filled Syringes and Injectable Drug Devices Conference 9 - 11 January London, UK Kick off 2024 and set the tone for the year at the 16th Annual Pre-Filled Syringes and Injectable Drug Devices Conference, which will return to London in January to unite leaders from the industry, bringing you the latest advances in the combination product drug Pharma EVENTS © stock.adobe.com/ tonstock © stock.adobe.com/ natali_mis 32 Pharma Business International www.pbiforum.net Tumor Models San Francisco 30 January - 1 February San Francisco, USA Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic development, and the domino effects across the field caused by the FDA Modernization Act 2.0, 2023 has set an exciting precedent for the upcoming year. However, the translation rates of oncology therapeutics into the clinic remain at 20%, proving there remains a large unmet need for tools to support drug development efforts in a patient-specific context at the preclinical and early translational levels. At the 8th Annual Tumor Models San Francisco Summit, you will gain practical insights into the latest updates across the West Coast and beyond through case studies that will empower your candidate selection workflows. Learn from and meet pioneers in preclinical and translational oncology to accelerate your candidate’s clinical translatability with optimized efficiency, and cost-effectiveness! more to harmonise cross-functional objectives and encourage an industry-wide push for more robust regulations that enable fast-paced innovations. RNA Therapeutics 6 - 8 February London, UK RNA therapeutics is a rapidly expanding delivery space and the chance to collaborate across a three day programme. Pharmapack 24 - 25 January Paris, France Pharmapack is the European hub for the pharma packaging and drug delivery device industry. Taking place annually in Paris, the event unites over 5,000 attendees and more than 300 exhibitors for two days of innovation, networking, and education. Attend to connect with other pharma professionals and expand your network at the heart of pharma. Medical Device Software Development Summit Europe 29 - 31 January Munich, Germany Dedicated to shedding light on the intricate layers of European regulation, integrated cybersecurity features and forecasted uncertainties around AI, the 2nd Medical Device Software Development Summit Europe serves as a pivotal platform to better align software innovation with compliance. Join over 80 experts in Software Engineering, Regulatory Affairs, R&D Operations, Product Management and industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious and chronic diseases. Don’t miss this opportunity to network with the big pharma and biotech community of global experts leading the way in RNA drug discovery and development. World ADC London 12 - 15 March London, UK Antibody-drug conjugates are coming of age with a remarkable surge in recent times, that has marked a turning point in their development. As such, the 14th World ADC London returns in March. This will be the first opportunity in the new year to explore monumental wins, reflect on ongoing challenges, and collaborate on innovative strategies to supercharge all stages of ADC development. www.pbiforum.net Pharma Business International 33 Gene Therapy Regulatory Affairs Summit 23 - 25 January Boston, USA As the first ever regulatory affairs forum wholly dedicated to gene therapy, this meeting uniquely unites regulatory bodies and the leading regulatory personnel across big pharma and innovative biotech to discuss the hottest topics, identify industry bottlenecks and offer actionable insights. Don’t miss out on this unrivalled opportunity to inform your trial design, perfect your CMC approach and supercharge your global submission strategy for regulatory success. © stock.adobe.com/ LALAKA AI in Drug Discovery 11 - 12 March London, UK Hear first-hand the latest AI advancements across the pharmaceutical sector directly from experts in the field and obtain strategies to support your operations at the highly anticipated AI in Drug Discovery conference. Driven by a move towards personalised therapies and novel drug candidates, Artificial Intelligence (AI) has taken the lead in technological advancement across the pharmaceutical sector. Increased efficiency of the drug discovery process, through innovations including automation, in-silico modelling, and machine learning, accelerate growth in an ever- expanding field, focused on revolutionising modern healthcare.FEATURES Laboratories Microbiology and R&D Pumps & Fluids Sorting & Weighing Health, Safety & Hygiene Next issue: Deadline - 31st January 2024 REGULARS News Events M&A Round-up Eye On Approvals Visit us at www.pbiforum.net where you’ll find the latest news as it breaks – and why not subscribe to our newsletters so you can have the latest news emailed to your inbox, in between digital issues? @pbiforumwww.pbiforum.netcompany/pbiforumNext >